Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BIOMERIEUX    BIM   FR0010096479

BIOMERIEUX

 (BIM)

471
Real-time Quote. Real-time Tradegate - 05/17 04:00:00 pm
74.189 EUR   +0.23%
04/23 BIOMERIEUX: - First-Quarter 2013 Business Review
04/18BIOMERIEUX SA: quaterly sales release
03/25 BIOMERIEUX: Veolia Environnement and bioMérieux initiate a research partne..
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisionsForum 
Sector
Healthcare
Healthcare Services
 Healthcare Equipment / Supplies
  Medical Equipment / Supplies / Distribution
Logo
Logo BIOMERIEUX
Business Summary
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (79.9%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (20.3%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Sales of reagents and services represent 87.4% of net sales.
Net sales break down geographically as follows: Europe/Middle East/Africa (51.4%), North America (22%), Asia/Pacific (18%) and Latin America (8.6%).
Surperformance© rating of BIOMERIEUX
Overall rating In sector In country
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Medical Equipment / Supplies / Distribution
CountryTrading RatingInvestor Rating
BAXTER INTERNATIONAL INC.USA
COVIDIEN PLCUSA
STRYKER CORPORATIONUSA
ESSILOR INTL.France
BECTON, DICKINSON AND CO.USA
ZIMMER HOLDINGS, INC.USA
COLOPLAST A/SDenmark
SMITH & NEPHEW PLCUnited Kingdom
TERUMO CORPJapan
C.R. BARD, INC.USA
HENRY SCHEIN, INC.USA
CAREFUSION CORPORATIONUSA
SONOVA HOLDING AGSwitzerland
SYSMEX CORPORATIONJapan
GETINGE ABSweden
DENTSPLY INTERNATIONAL INC.USA
THE COOPER COMPANIES, INC.USA
WILLIAM DEMANT HOLDING A/SDenmark
SHANDONG WEIGAO GROUP MEDICAL POLYMER COHONG KONG
PATTERSON COMPANIES, INC.USA
BIOMERIEUXFrance
BIO-RAD LABORATORIES, INC.USA
TELEFLEX INCORPORATEDUSA
ALIGN TECHNOLOGY, INC.USA
STERIS CORPUSA
Sector Medical Equipment / Supplies / Distribution
Data source :
© 2013 Thomson Reuters
Ratings :
© 2013 Surperformance
Shareholders
- Institut Mérieux 58,90%
- GIMD 5,10%
- Employees 0,91%
- Company-owned shares 0,07%
Advertisement
Managers
- Deputy CEO :
    Alexandre Mérieux
- General Secretary :
    Henri Thomasson
- Chairman and Chief Executive Officer :
    Jean-Luc Bélingard
Company contact information

FR-69280 Marcy-l'Etoile
France

Phone : +33 (0)4 78 87 20 00
Fax : +33 (0)4 78 87 20 90
Internet : http://www.biomerieux.com
Markets and indexes
- PEA / SRD eligible : YES / YES
- NYSE Euronext Paris
- Compartiment A
- CAC All Shares / CAC All-Tradable, CAC Mid 60, CAC Mid Small, Next 150, SBF 120
Stock Exchange Codes
- ISIN Code :  FR0010096479
- Bloomberg Code :  BIM:FP
- Reuters Code :  BIOX.PA
- Datastream Code :  
Financial data source :
© 2013 Cofisem
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.